RxDoctor Payments Data

Melissa Scott, APRN

Family · Eastover, SCNPI 1871133728

Payments from drug & device makers

$900in general payments, 2019–2025

Across 44 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$285
  • AbbVie$237
  • Novo Nordisk$211
  • Exact Sciences$46
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$30
  • Edwards Lifesciences$26
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$900100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$900 in reported general payments places this provider in the 65th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$833
Medicare patients
47
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Janumet XrSitagliptin Phos/Metformin Hcl101$77,368
OzempicSemaglutide69$68,492
EliquisApixaban56$48,209
JardianceEmpagliflozin56$48,004
XareltoRivaroxaban37$33,623
JanuviaSitagliptin Phosphate36$24,096
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$20,075
Tresiba Flextouch U-100Insulin Degludec27$19,718
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$18,975
LinzessLinaclotide18$13,614
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$9,209
Tresiba Flextouch U-200Insulin Degludec11$8,003
Triamcinolone Acetonide50$7,849
Repatha SureclickEvolocumab12$6,337
Humalog Kwikpen U-100Insulin Lispro21$5,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$211$68,49269 claims
Johnson & JohnsonXarelto$17$33,62337 claims
AbbVieLinzess$237$13,61418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,248 family providers in South Carolina.

Other family in Eastover

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →